Nazione: Israele
Lingua: inglese
Fonte: Ministry of Health
PENTOXIFYLLINE
DEXCEL LTD, ISRAEL
C04AD03
CAPLETS PROLONGED RELEASE
PENTOXIFYLLINE 400 MG
PER OS
Required
DEXCEL LTD, ISRAEL
PENTOXIFYLLINE
PENTOXIFYLLINE
For the improvement of blood flow in the peripheral blood vessels.
2020-09-30
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Oxopurin 400 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each prolonged release caplet contains Pentoxifylline 400mg. Excipient with known effect: Each caplet contains approximately 105mg lactose. For the full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Prolonged release caplet. Pink, film-coated, caplet, scored on both sides. The score line is not intended for breaking the caplet. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the improvement of blood flow in the peripheral blood vessels. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION CHRONIC PERIPHERAL ARTERIAL OCCLUSIVE DISEASE AT FONTAINE STAGE IIB (INTERMITTENT CLAUDICATION) Unless otherwise prescribed, 1 Oxopurin 400mg prolonged-release caplet three times daily (equivalent to 1,200 mg pentoxifylline per day). Special dosage instructions may be necessary for patients with low or fluctuating blood pressure levels. In patients with impaired renal function (creatinine clearance less than 30 ml/min), the dose should be titrated to 50–70% of the standard dose, depending on individual tolerability, e.g. by taking 400 mg pentoxifylline twice daily instead of 400 mg pentoxifylline three times a day. In the case of patients with severe hepatic dysfunction, a dose reduction is required, which should be decided by the doctor on an individual basis according to the severity of the illness and tolerability. INNER EAR DYSFUNCTION CAUSED BY CIRCULATORY DISORDERS (INCLUDING HARDNESS OF HEARING, SUDDEN HEARING LOSS). Unless otherwise prescribed, 1 Oxopurin 400mg prolonged-release caplet twice daily or three times a day (equivalent to 800–1,200 mg pentoxifylline per day). In cases of severe circulatory disturbances, a combination with parenterally administered Pentoxifylline 100 mg or 300 mg ampoules (IV infusion) can accelerate the onset of action. The total daily dose (parenteral + oral) should essentially not exceed 1,200 mg pentoxifylline. Depending on Leggi il documento completo